GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (FRA:SCP) » Definitions » Net Current Asset Value

Scancell Holdings (FRA:SCP) Net Current Asset Value : €-0.02 (As of Oct. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Scancell Holdings Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Scancell Holdings's net current asset value per share for the quarter that ended in Oct. 2023 was €-0.02.

The historical rank and industry rank for Scancell Holdings's Net Current Asset Value or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Scancell Holdings was 26.02. The lowest was 2.50. And the median was 7.98.

FRA:SCP's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 3.975
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Scancell Holdings Net Current Asset Value Historical Data

The historical data trend for Scancell Holdings's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings Net Current Asset Value Chart

Scancell Holdings Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.01 0.01 - -0.02

Scancell Holdings Semi-Annual Data
Apr14 Oct14 Apr15 Oct15 Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 - 0.01 -0.02 -0.02

Competitive Comparison of Scancell Holdings's Net Current Asset Value

For the Biotechnology subindustry, Scancell Holdings's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scancell Holdings's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's Price-to-Net-Current-Asset-Value falls into.



Scancell Holdings Net Current Asset Value Calculation

Scancell Holdings's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Apr. 2023 is calculated as

Net Current Asset Value Per Share(A: Apr. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(27.946-41.458-0-0)/819.221
=-0.02

Scancell Holdings's Net Current Asset Value (NCAV) per share for the quarter that ended in Oct. 2023 is calculated as

Net Current Asset Value Per Share(Q: Oct. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(19.619-35.314-0-0)/819.982
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scancell Holdings  (FRA:SCP) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Scancell Holdings Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Scancell Holdings (FRA:SCP) Business Description

Traded in Other Exchanges
Address
Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (FRA:SCP) Headlines

No Headlines